Key Identity Verification Trends for 2025: Regula's Expert Insights
Regula, a global developer of forensic devices and identity verification solutions, unveils its vision for the identity verification (IDV) industry in 2025. As new and persistent threats converge with evolving regulations and user expectations, they bring to life new requests for significant technological advancements in IDV.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250121753818/en/
Regula's experts share their insights into how identity verification will evolve in 2025 (Graphic: Regula)
Threats shaping the IDV landscape
The rise in identity fraud over the past two years has significantly impacted all industries, especially Finance, Banking, FinTech, and Crypto. With deepfakes threatening every second company around the world, businesses won’t be able to stand out without liveness checks, both for biometrics and documents. However, organizations can’t blindly rely on this method as-is. They will have to introduce signal source control viahardware-enabled solutions. With deepfakes being so deeply realistic now, humans often fail to distinguish between what is fake and what is real. That is why checking signal source integrity is crucial, as it helps ensure that no injection is done during the video session within the IDV process.
Also, businesses will further reinforce their biometric verification methods, such as facial recognition, fingerprint scanning, and voice identification, as they add additional defense.
Interestingly, traditional threats like fake IDs and synthetic fraud still account for the majority of identity fraud attempts. This highlights the need for businesses to balance preparing for sophisticated future attacks with addressing the more prevalent threats of today.
Regulations and user expectations: Growing demand and pressure
The IDV landscape is evolving due to stricter laws, rising user expectations, and new workforce demands. Governments are enforcing tighter age verification to protect minors and regulate restricted services. This will be driving further technologies like biometric age estimation.
Users seek fast, personalized IDV solutions, while businesses require flexible systems. So, the IDV industry will continue developing toward user-centric design, where convenience and personalization are prioritized.
Additionally, a new IDV user category is emerging: the workforce. In the era of remote and hybrid work, identity verification for employees is critical to prevent fraud, such as fake identities and ghost employees.
Technological shifts
The evolving challenges of fraud, compliance, and user demands are driving advancements in IDV technologies and the adoption of new digital identity documentslike the Digital Travel Credential (DTC), mobile driver’s licenses (mDLs), digital identity, etc.
To ensure more efficient fraud prevention, identity verification will extend beyond traditional document and biometric checks to include additional methods, such as direct validation against governments’ or issuing authorities’ databases. Also, IDV technologies will be more deeply integrated with other IT solutions deployed in organizations to create secure ecosystems.
Journey Time Orchestration (JTO) is gaining traction, offering a dynamic platform approach to managing identity tasks across the user journey by unifying biometrics, passwords, and third-party systems to balance security and convenience.
Last but not least, AI and ML technologies will be gaining momentum in identity verification. They have been used in IDV solutions for some time already, but their influence will become more tangible as AI-generated fraud evolves into a very significant threat to businesses worldwide.
“The identity verification industry is driven by the multiple forces of advanced threats, rising user demands, tightening regulation, and technological advancements. As we move into 2025, the challenge will be to create solutions that not only address sophisticated fraud but also prioritize user convenience and regulatory compliance,” said Ihar Kliashchou, Chief Technology Officer at Regula.
To get more insights on the trends that will shape IDV in the coming year, read our blog article.
About Regula
Regula is a global developer of forensic devices and identity verification solutions. With our 30+ years of experience in forensic research and the most comprehensive library of document templates in the world, we create breakthrough technologies for document and biometric verification. Our hardware and software solutions allow over 1,000 organizations and 80 border control authorities globally to provide top-notch client service without compromising safety, security, or speed. Regula has been repeatedly named a Representative Vendor in the Gartner® Market Guide for Identity Verification.
Learn more at www.regulaforensics.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250121753818/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom